Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Androgen deprivation has been the standard therapy for advanced and metastatic prostate cancer for over half a century, as prostate tumors are initially dependent on androgens for growth and survival. Unfortunately, in most patients undergoing androgen ablation, relapse (recurrent tumor growth) eventually occurs. The actions of the principal androgens, testosterone and dihydrotestosterone (DHT), are mediated via androgen receptors (ARs), ligand‐activated transcription factors that belong to the nuclear receptor superfamily. Because of the presence of transcriptionally active ARs in tumors from recurrent or androgen‐independent disease, there is a heightened interest in new therapeutic paradigms that target the AR and its regulatory pathways. The regulation of AR levels is highly complex with control exerted by several pathways and in a cell‐, tissue‐, and developmental‐stage specific manner. Androgens are important regulators of AR mRNA and protein through transcriptional and post‐transcriptional mechanisms. This article reviews the evidence implicating the AR in recurrent prostate cancer and discusses the multiple mechanisms that regulate AR levels in normal and neoplastic cells. The complexity of AR regulation suggests that there will be an ample array of potential new drug targets for modulating levels of this receptor, a key signaling molecule in prostate cancer. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“These mutations thus permit AR to regulate targets genes in response to other hormones or even AR antagonists [reviewed in Feldman and Feldman, 2001].”
BackgroundMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 2×
“As discussed above, upregulation of AR can drive progression to androgen-independent prostate cancer [Chen et al., 2004].”
BackgroundAndrogen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 2×
“Increased expression of AR in advanced prostate cancer can result from AR gene amplification, which occurs in approximately 30% of advanced prostate cancers [Visakorpi et al., 1995].”
BackgroundAndrogen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943 · cited 2×
“AR homodimers recruit a panoply of factors including coactivators and mediator proteins whose enzymatic activities promote chromatin remodeling and transcriptional regulation of target genes leading to cell differentiation, survival, and proliferation [reviewed in Heinlein and Chang, 2002a].”
BackgroundThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 1×
“The results from experimental models of prostate cancer progression and from analysis of androgen levels in human prostate cancer clinical samples have prompted a reconsideration of terminology [Mohler et al., 2004].”
BackgroundThe Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions
Heinlein, C. A., & Chang, C. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0070 · Cited by 568 · cited 2×
“AR homodimers recruit a panoply of factors including coactivators and mediator proteins whose enzymatic activities promote chromatin remodeling and transcriptional regulation of target genes leading to cell differentiation, survival, and proliferation [reviewed in Heinlein and Chang, 2002a].”
BackgroundWallace, A. D., & Cidlowski, J. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106033200 · Cited by 394
The Current State of Hormonal Therapy for Prostate Cancer
Hellerstedt, B. A., & Pienta, K. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.3.154 · Cited by 386
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · cited 5×
“…analyses in advanced prostate cancers as well as from prostate cell and transgenic mouse models expressing AR strongly support the significance of AR expression and regulation in prostate adenocarcinoma [Stanbrough et al., 2001; Berger et al., 2004; Mellinghoff et al., 2004; Shah et al., 2004].”
BackgroundInfluential
Cited by
Testosterone and cortisol jointly regulate dominance: evidence for a dual-hormone hypothesis
Mehta, P. H., & Josephs, R. A. (2010) · Hormones and Behavior · doi:10.1016/j.yhbeh.2010.08.020 · Cited by 574
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0968 · Cited by 229
“known to be androgen-regulated (28, 29)] between the medically castrate group and the control subjects (Table 3).”
Background
Metadata
- Authors
- Burnstein, K. L.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2005-04-28
- Volume
- 95
- Issue
- 4
- Pages
- 657-669
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2059968629
- Cited by
- 118
- References
- 13
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.